Opinion|Videos|June 26, 2024
Monitoring Adverse Events Following CAR T-Cell Therapy
A panel of oncologists in academic and community settings discuss patient monitoring practices following CAR T-cell infusions, with a focus on neurotoxicities.
Advertisement
Episodes in this series
- Dr. Usmani: What is your protocol for monitoring and grading of neurotoxicity, cytokine release syndrome (CRS), and other acute toxicities immediately following CAR-T cell infusion?
- Are there any subgroups of patients you have found to be at particularly high risk for delayed neurotoxicity requiring extended monitoring?
- What are your institutional guidelines around administering steroids, anti-seizure medications, or other treatments for severe neurotoxicity?
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
3
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
4
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
5